SCHEMBL15467737

SCHEMBL15467737

OC1(c2cccc(OC(F)(F)F)c2)CCOc2cccnc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.45
HDAC6 Q9UBN7 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
PKLR P30613 1/20 0.38
MAP3K14 Q99558 2/20 0.37
GRM5 P41594 1/20 0.36
KCNH2 Q12809 4/20 0.36
CYP2D6 P10635 3/20 0.36
CYP2C9 P11712 3/20 0.36
GPR142 Q7Z601 3/20 0.36
PDE4B Q07343 1/20 0.35
PDE4D Q08499 1/20 0.35
MAOB P27338 1/20 0.34
RXRA P19793 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
ICMT O60725 1/20 0.34
HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467465 0.87 TRPM8 (0.51) TRPM8MAP3K14KCNH2PDE2ASCN1A
SCHEMBL15466993 0.83 TRPM8 (0.42) TRPM8PDE2A
SCHEMBL15469368 0.80 MAP3K14 (0.44) TRPM8HDAC6HDAC3HDAC1HDAC2
SCHEMBL16414170 0.79 TRPM8 (0.49) TRPM8HDAC6HDAC3HDAC1HDAC2
SCHEMBL15467914 0.78 MAP3K14 (0.49) TRPM8MAP3K14GRIN2B
SCHEMBL15467528 0.78 TRPM8 (0.62) TRPM8HDAC6HDAC3HDAC1HDAC2
SCHEMBL15467530 0.78 TRPM8 (0.62) TRPM8HDAC6HDAC3HDAC1HDAC2
SCHEMBL15467331 0.76 PDE2A (0.38) TRPM8HDAC6HDAC3HDAC1HDAC2
SCHEMBL15467986 0.76 TRPM8 (0.37) TRPM8MAP3K14PDE2ASCN9A
SCHEMBL15468024 0.74 MAP3K14 (0.38) TRPM8MAP3K14GRIN2BCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885HDAC6 1685/4885HDAC3 965/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885HDAC6 1685/4885HDAC3 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.